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Abstract 23 
Objective: To evaluate if gabapentin 600 mg reduces pain after osmotic dilator placement the day before 24 
a dilation and evacuation (D&E) procedure. 25 
Study Design: We conducted a double-blind, placebo-controlled, randomized (stratified by vaginal 26 
parity) trial among women undergoing osmotic dilator placement before D&E at 15 to 23 5/7 weeks 27 
gestation. Subjects received gabapentin 600 mg or placebo 30 minutes before dilator placement, with re-28 
dosing 8 hours later. We assessed pain after dilator placement using a numeric rating scale (NRS; scale 0-29 
10) at 5 minutes, 2, 4, and 8 hours, and at presentation for D&E. The primary outcome was median NRS 30 
pain score change from baseline to 8 hours after dilator placement. Secondary outcomes included 31 
gabapentin-related side effects and analgesic use.  32 
Results: Of 121 randomized women, we excluded three subjects (allergic reaction [placebo], 33 
randomization error, no NRS data), leaving 60 gabapentin and 58 placebo subjects. Of 110 (93%) women 34 
who provided 8-hour data, median pain score changes from baseline did not differ between gabapentin 35 
and placebo groups overall (2 vs. 2.5, p=0.52), in vaginally nulliparous women (2 vs. 4, p=0.10) or in 36 
parous women (2 vs. 1.5, p=0.37).  We found no statistically significant differences in median pain score 37 
change from baseline to any timepoint overall or when stratified by parity. Beginning at 2 hours after 38 
dilator placement, more gabapentin than placebo users experienced dizziness (29/53[55%] vs. 39 
11/53[21%], p=0.001) and tiredness (34/54[63%] vs. 17/54[31%], p=0.002). The proportion of women 40 
using narcotics did not differ between gabapentin (35/60[58%]) or placebo (40/58[69%]) users (p=0.26). 41 
Conclusions: Gabapentin does not reduce pain with overnight osmotic dilator placement prior to D&E 42 
and causes drug-related side effects.  43 
 44 
Keywords: gabapentin; abortion; dilation and evacuation; osmotic dilators; pain; text message  45 
3 
Implications Statement: Women experience pain, mostly mild to moderate, with overnight cervical 46 
dilator placement at 15-23 5/7 weeks gestation. About 2/3 of women will use a limited quantity of 47 
narcotics if provided. Gabapentin does not decrease the pain with or following dilator placement and does 48 
not decrease narcotic use.49 
4 
1.0  Introduction 50 
Osmotic dilators are commonly used for cervical preparation prior to dilation and evacuation 51 
(D&E) procedures. Cervical anesthesia reduces pain with dilator placement [1]; however, most research 52 
to date has focused on dilators and ease of D&E completion, evaluating pain as a secondary outcome [2-53 
5]. Insertion of dilators can be more painful than pharmacological cervical preparation, and accounts of 54 
how this pain changes over time vary [3,4,6]. One trial evaluating use of intrauterine lidocaine for pain 55 
relief during laminaria placement asked participants 30 minutes before D&E to self-report their maximum 56 
pain level using a visual analog scale (VAS) since dilator insertion; mean pain scores for the post-57 
laminaria interval were higher than those recorded at laminaria insertion (44 vs 32 p=.04) [2]. Women’s 58 
experience with pain during the time between dilator insertion and D&E remains an under-evaluated 59 
aspect of their abortion experience. 60 
Multimodal pain management is an area of interest across many procedural fields. Providers vary 61 
in their strategies for pain management after dilator insertion and may recommend over-the-counter 62 
analgesics alone or prescribe oral narcotics. Given the potential for narcotic addiction, studies have been 63 
investigating non-narcotic analgesic adjuncts such as gabapentin for various obstetric and gynecologic 64 
procedures. Gabapentin is an attractive medication because it is low-cost, non-addictive, and has few 65 
medical contraindications for use [7]. Studies regarding preoperative use of gabapentin in abdominal 66 
hysterectomy have demonstrated decreased post-operative narcotic use, decreased nausea and vomiting, 67 
and increased patient satisfaction [8-13]. A systematic review demonstrated a significant benefit of pre-68 
operative gabapentin for preemptive analgesia for abdominal hysterectomy [14]. Data regarding 69 
preoperative gabapentin use in other contexts, such as Cesarean delivery and laparoscopic ovarian 70 
cystectomy, are less consistent [15-20]. The heterogeneity of gabapentin dosing and overall pain regimen 71 
along with study design limitations make these data challenging to generalize to abortion procedures. The 72 
goal of this study is to evaluate the effect of gabapentin on pain experienced after osmotic dilator 73 
placement prior to D&E.   74 
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2.0  Materials and methods 75 
We conducted this randomized, double-blind, placebo-controlled trial at the University of 76 
California, Davis Medical Center. We enrolled women 15 weeks 0 days to 23 weeks 5 days gestation on 77 
the day prior to a planned D&E procedure for whom the surgical plan included osmotic dilator placement 78 
for overnight cervical preparation. We included women 18 years or older, English-speaking, with an 79 
active cell phone with text messaging capabilities, and a ride home from clinic. We excluded women 80 
currently taking gabapentin, with an allergy to gabapentin or our standard clinic analgesics (ibuprofen or 81 
acetaminophen with codeine), with active renal disease, or currently using narcotics. The UC Davis 82 
Institutional Review Board approved this study and all study subjects gave written consent prior to 83 
enrollment.  84 
After obtaining baseline demographic information, we randomized subjects 1:1, with 85 
stratification based on vaginal parity, to receive two doses of gabapentin 600 mg or placebo. Subjects 86 
took the first study drug dose after randomization and instructed to take the second dose 8 hours after 87 
dilator placement. The UC Davis Investigational Drug Service (IDS) over-encapsulated the study drug 88 
and placebo tablets to create identical-appearing medication. The IDS performed the randomization 89 
allocation using a computer-generated random sequence in blocks of four for two groups (vaginally 90 
nulliparous and vaginally parous), prepared sequentially numbered vials for each group with appropriate 91 
treatment, and maintained the randomization log to ensure drug allocation concealment until study 92 
completion. 93 
Family Planning fellows or Obstetrics and Gynecology residents under the supervision of Family 94 
Planning faculty aimed to place osmotic dilators 30-60 minutes after intake of the first study drug dose. 95 
All physicians followed a standardized clinic protocol for dilator placement (online Appendix Figure 1) 96 
using 4 mm Dilapan-S® and cervical anesthesia with lidocaine 1% 20 mL. We used adjunctive 97 
mifepristone for gestations 22 or more weeks or if the physician placed fewer than the preferred number 98 
of dilators. Subjects in this study did not receive misoprostol. We gave each subject prescriptions for 20 99 
tablets each of ibuprofen 800 mg (1 tablet every 8 hours as needed) and acetaminophen with codeine 100 
6 
300/30 mg (1-2 tablets orally every 4-6 hours as needed) with instructions to use these medications as 101 
needed for pain management after dilator insertion. 102 
We evaluated pain using an 11-point numeric rating scale score (NRS; scale 0-10) and assessed 103 
gabapentin-specific side effects of tiredness and dizziness. We asked each subject to verbally provide a 104 
baseline NRS score and side effect responses at the time of study drug intake and then at 5 minutes after 105 
dilator placement. Each subject received text messages at 2, 4, and 8 hours after dilator placement to 106 
ascertain current NRS scores for pain, perceived tiredness or dizziness, and the quantity of interval 107 
analgesic use (ibuprofen and acetaminophen with codeine). The 8-hour text included a prompt to take the 108 
second dose of study drug. Upon presentation for D&E procedure the subsequent day (approximately 18-109 
24 hours after dilator placement), we asked the subject to verbally provide a NRS pain score, current 110 
tiredness or dizziness, and analgesic use since the 8-hour text message. 111 
The primary outcome was median change in NRS score from baseline to 8 hours post dilator 112 
insertion. We assessed median change in individual pain score from baseline, as opposed to median group 113 
scores at each time point, because using median change in individual pain score has been adopted in other 114 
fields as the preferred standard for evaluating pain management [20]. Secondary outcomes included pain 115 
score change at other time points, difference in pain scores by gestational age, study drug side effects, and 116 
analgesic use. Additionally, we assessed median group pain scores at all post-dilator placement time 117 
points to describe women’s pain experience with overnight dilator placement. Because narcotic pain 118 
medications can impact both pain and side effects, we also performed an analysis of these outcomes in 119 
women who did not use narcotics. 120 
We estimated a sample size based on a prior study that utilized an 11-point NRS to assess 121 
immediate post dilator pain as a secondary outcome, reporting a mean score of 5.2 ± 1.2 [4]. We 122 
calculated 12 women per group would demonstrate a clinically meaningful pain difference of 2-points on 123 
NRS with 80% power and α=0.05 [21]. We doubled the sample to allow for stratification by vaginal 124 
parity, and then doubled the size again to 48 per group to allow for adequate evaluation of the primary 125 
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and secondary outcomes. We increased the sample by 20% to account for incomplete follow-up or other 126 
limitations, yielding a final sample of approximately 120 women. 127 
We performed a modified intention-to-treat analysis, including only women who provided any 128 
follow-up NRS information. We compared baseline characteristics among treatment groups using Fisher’s 129 
Exact Test or Chi-square test as indicated, t-test for continuous variables, and Mann Whitney U for 130 
comparing median pain scores. We categorized pain scores post hoc as none, mild (1-3), moderate (4-6), 131 
or severe (7-10). We completed analyses using SPSS version 25 (Armonk, NY). 132 
 133 
3.0  Results 134 
We randomized 121 women from March 2017 to April 2018 and excluded 3 women from the 135 
outcome analysis, one due to randomization error, one due to an allergic reaction after dilator placement 136 
who had received placebo, and one who did not provide any follow-up NRS data (Figure 1). The 137 
characteristics of the 118 women (60 in the gabapentin group and 58 in the placebo group) who 138 
completed the study are presented in Table 1. The mean gestational age for the population was 19 weeks 139 
3 days. Physicians completed dilator placement 42.3 ± 11.2 minutes after initial study drug intake in the 140 
gabapentin group and 44.2 ± 9.8 minutes in the placebo group (p=0.33). Nine (15%) and 15 (26%) 141 
women, respectively, received mifepristone. The final study evaluation occurred 22.8 ± 2.0 hours and 142 
22.9 ± 1.8 hours, respectively, after dilator placement (p=0.91). 143 
Median change in NRS pain score from baseline is presented in Table 2. Fifty-eight (97%) 144 
women in the gabapentin group and 52 (88%) women in the placebo group provided 8-hour NRS 145 
responses, the primary outcome. Median change in pain score from baseline to 8 hours post-dilator 146 
placement did not differ (2 vs. 2.5, p=0.52); this absence of effect persisted at all time points after dilator 147 
placement (5 minutes, 2 hours, 4 hours, and 18-24 hours). When evaluating median change in NRS scores 148 
by parity, we found no statistical differences between gabapentin and placebo users at any time point, 149 
though we did observe a clinically significant difference of 2 points at 5 minutes, 4 hours and 8 hours 150 
(Table 2). 151 
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When evaluating population median values at each time point, we also found no differences in 152 
scores at all post-dilator placement time points among treatment groups stratified by vaginal parity except 153 
for a 2-point difference at 8 hours in vaginally nulliparous women (online Appendix Figure 2). 154 
Participants provided a very wide range of pain scores at each time point. 155 
Women who received gabapentin reported more dizziness or tiredness, both of which reached 156 
statistical significance compared to placebo beginning at 2-hours after dilator placement (Figure 2). More 157 
gabapentin than placebo users experienced dizziness at 2 (29/53[55%] vs. 11/53[21%], p=0.001), 4 158 
(22/55[40%] vs. 5/50[10%], p=0.001) and 8 hours (15/57[26%] vs. 3/52[6%], p=0.004) and tiredness at 2 159 
(34/54[63%] vs. 17/54[31%], p=0.002) and 4 hours (37/54[69%] vs. 18/51[35%], p=0.001).  160 
Table 3 describes the proportion of women who used pain medication during the time from 161 
dilator placement to evaluation in the pre-operative area based on the 118 women who provided responses 162 
to analgesic use questions. Most (98 [83%]) women used some analgesia, with 85 (73%) women 163 
reporting any ibuprofen use and 75 (64%) reporting any acetaminophen with codeine use. Women who 164 
reported higher NRS pain scores more commonly used acetaminophen with codeine than ibuprofen or no 165 
pain medication (Table 3). Acetaminophen with codeine use did not differ between gabapentin 166 
(35/60[58%]) and placebo (40/58[69%]) users (p=0.26). Use of ibuprofen or acetaminophen with codeine 167 
did not differ by parity, with ibuprofen use by 45 (76%) vaginally nulliparous and 40 (68%) vaginally 168 
parous women (p=0.4) and acetaminophen with codeine use by 40 (68%) and 35 (59%), respectively 169 
(p=0.4). Few women (n=12, 10%) reported using six or more acetaminophen with codeine tablets, 170 
distributed equally among vaginally nulliparous (n=6) and parous (n=6) subjects; the maximum number 171 
used was 11.  172 
When stratifying by gestational age (≤19 weeks 6 days or ≥ 20 weeks 0 days), we found no 173 
difference in maximum reported NRS pain score (median 5 vs 6, p=0.57) or any acetaminophen with 174 
codeine use (46/74 [62%] vs. 29/44 [66%], p=0.70). When evaluating pain and side effect outcomes in 175 
women who did not use any narcotic (25 gabapentin and 18 placebo subjects), we found no difference in 176 
median 8-hour NRS change from baseline (1 vs. 2, p=0.41), maximum reported NRS pain score (median 177 
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3 vs 3, p=0.96), or side effect profiles between gabapentin and placebo users (data not shown). Sub-178 
analysis of the women who received mifepristone showed no difference between gabapentin and placebo 179 
users in median 8-hour NRS change from baseline (3 vs. 3, p=0.93), maximum reported NRS pain score 180 
(median 7 vs 7, p=0.86) or any acetaminophen with codeine use (5/9 [56%] vs. 10/15 [67%], p=0.68). 181 
We describe the overall pain experience of women with overnight dilator placement by reporting 182 
median NRS pain scores and severity for the placebo group only in Table 4. Two of these women 183 
reported zero on NRS pain scale at all time points; both were less than 20 weeks gestation and vaginally 184 
parous. 185 
 186 
4.0  Discussion 187 
Gabapentin 600 mg with repeat dosing at 8 hours did not improve pain with overnight osmotic 188 
dilators prior to D&E procedure. Gabapentin had some clinical effect as demonstrated by the timely 189 
reports of dizziness and tiredness among women who received gabapentin compared to placebo, primarily 190 
over the first four hours after initial ingestion. Since both time points occurred in the afternoon prior to 191 
onset of a typical evening sleeping schedule, we conclude that the excess dizziness and tiredness are 192 
consistent with known drug side effects. These effects did not result in less narcotic use by women 193 
receiving gabapentin. 194 
In the subset of vaginally nulliparous women, median pain score changes at 5 minutes, 4 hours, 195 
and 8 hours from baseline met our a priori designated 2-point clinical difference when comparing 196 
gabapentin and placebo groups. Although we recruited a study sample large enough for these differences 197 
to be assessed, the outcomes did not achieve statistical significance. We believe the lack of statistical 198 
significance is related to the very wide range in responses in both groups, demonstrating the variability in 199 
pain experience for each patient. Although gabapentin may provide a benefit for vaginally nulliparous 200 
women, we found these women experienced more dizziness and tiredness without a resultant decrease in 201 
narcotic use. Thus, the relevant benefit may be negligible. Further research of nulliparous women may 202 
identify who may benefit from gabapentin prior to osmotic dilator placement. 203 
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The lack of a clear benefit with gabapentin use correlates with a recently reported double-blind 204 
randomized trial demonstrating that gabapentin did not reduce postoperative pain with first trimester 205 
surgical abortion [22]. When considering these findings together with the benefit of pre-emptive 206 
gabapentin for pain reduction with abdominal hysterectomy [8-14], and the slight and variable pain 207 
reduction benefit with cesarean delivery [15-20], perhaps gabapentin is more beneficial for incision-208 
related (sensory) pain and less for uterine cramping related (visceral) pain. 209 
The medical literature lacks primary data on women’s pain experience with dilator placement. 210 
Our placebo group provides explicit information about the pain experience with overnight dilators. 211 
Nulliparous women generally experience moderate pain after Dilapan-S placement, commonly peaking at 212 
2 hours, and may remain the same for at least 6 more hours. Pain for multiparous women appears to peak 213 
at 4 hours and decline thereafter. This information will aid providers in patient counseling regarding pain 214 
expectations in the hours following osmotic dilator placement. Future studies should more carefully 215 
assess the pain course in vaginally nulliparous women more than 8 hours after dilator placement.   216 
The broad range of pain scores indicates that some women experience more severe pain. By the 217 
time of presentation for D&E the next day, the pain level reported is lower than what is reported at 8 218 
hours after dilator placement in parous women but not in nulliparous women, of whom about 20% are 219 
still reporting severe pain. We found a correlation of the maximum pain score with acetaminophen with 220 
codeine use but not with ibuprofen use, demonstrating that women who experience severe pain will use a 221 
narcotic when available, albeit generally fewer than 6 tablets. In our practice we now prescribe fewer 222 
narcotic tablets initially and have instituted a mechanism for providing additional analgesics overnight to 223 
women who continue to experience pain after finishing their supply. 224 
We measured our dilator placement pain score 5 minutes after dilator placement to assess pain 225 
free of other factors, including anxiety, that could affect pain at the moment of placement.  Prior studies 226 
have evaluated pain score at time of speculum removal. Schivone et al [23] enrolled 69 women 18 weeks 227 
or greater (mean 19 weeks) in an open-label randomized trial comparing lidocaine gel and lidocaine 1% 228 
12 mL paracervical block for pain control during dilator placement. The investigators reported a median 229 
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visual analog scale pain score (based on a 10 cm line) of 2.5 cm with gel and 3.9 cm with the paracervical 230 
block (p=0.17) with peak pain in both groups during dilator placement. Borgatta et al [4] enrolled women 231 
14-16 weeks gestation who received ibuprofen or ketorolac and a cervical anesthetic with lidocaine 1% 232 
10 mL prior to placement of 3-6 osmotic dilators (both laminaria and Dilapan, mean 5), resulting in a 233 
mean NRS pain score of 5.2 (95% CI 4.0-6.4). Our median NRS pain score 5 minutes after dilator 234 
placement of 1-2 is much lower than reported in both studies, likely reflecting how quickly the pain 235 
decreases for most women after speculum removal. Of note, the Borgatta et al [4] study did not prescribe 236 
oral narcotics to have at home; 2/25 (8%) women made visits to the emergency department overnight to 237 
obtain narcotic pain medication. The need for narcotics in this study may reflect the use of more dilators 238 
than needed at this gestational age, potentially resulting in more pain [24]. 239 
A strength of our study is its large size which allowed ample numbers to evaluate overall 240 
outcomes as well as differences related to parity. Additionally, physicians minimized variation by 241 
maintaining a standardized osmotic dilator placement protocol across the five family planning 242 
subspecialists, two fellows, and residents who provided care to study participants. The study was limited 243 
by the enrollment criteria stipulating that participants must have a ride home from the outpatient osmotic 244 
dilator placement visit and must have a private cell phone not shared by others; both criteria could 245 
disproportionately restrict enrollment of women with limited support or resources. Additionally, the 246 
findings may be specific to the dilator regimen used in these participants and may not apply to other 247 
osmotic dilator protocols. 248 
Though use of adjunctive non-opioid analgesics remains an important focus for abortion care, we 249 
showed that gabapentin does not provide benefit for osmotic dilator-associated pain compared to placebo. 250 
Women experienced gabapentin side effects but no primary benefit in pain reduction or decrease in 251 
narcotic use. We also describe that some women experience significant pain with overnight dilator 252 
placement and may utilize a narcotic prescription. The decision to prescribe narcotics should be 253 
individualized based on discussions with the patient. The description of the pain women experience 254 
12 
following dilator insertion and the associated analgesic use will allow clinicians to provide better 255 
counseling and adequately titrate pain medication prescriptions. 256 
 257 
Funding: Society of Family Planning Research Fund #17-08; the funder had no role in study conduct, data 258 
interpretation, or manuscript preparation or approval 259 
Disclosures: None 260 
Acknowledgements: None  261 
13 
References 262 
[1] Soon R, Tschann M, Salcedo J, Stevens K, Ahn HJ, Kaneshiro B. Paracervical block for 263 
laminaria insertion before second-trimester abortion: A randomized controlled trial. Obstet 264 
Gynecol 2017;130:387-92. 265 
[2] Mercier RJ, Liberty A. Intrauterine lidocaine for pain control during laminaria insertion: a 266 
randomized controlled trial. Contraception 2014:90;594-600. 267 
[3] Sagiv R, Mizrachi Y, Glickman H, Kerner R, Keidar R, Bar J, et al. Laminaria vs. vaginal 268 
misoprostol for cervical preparation before second-trimester surgical abortion: a randomized 269 
clinical trial. Contraception 2015;91:406-11. 270 
[4] Borgatta L, Roncari D, Sonalkar S, Mark A, Hou MY, Finneseth M, et al. Mifepristone vs. 271 
osmotic dilator insertion for cervical preparation prior to surgical abortion at 14-16 weeks: a 272 
randomized trial. Contraception 2012;86:567-71. 273 
[5] Drey EA, Benson LS, Sokoloff A, Steinauer JE, Roy G, Jackson RA. Buccal misoprostol plus 274 
laminaria for cervical preparation before dilation and evacuation at 21-23 weeks of gestation: a 275 
randomized controlled trial. Contraception 2014;89:307-13. 276 
[6] Prairie BA, Lauria MR, Kapp N, Mackenzie T, Baker ER, George KE. Mifepristone versus 277 
laminaria: a randomized controlled trial of cervical ripening in midtrimester termination. 278 
Contraception 2007;76:383-8. 279 
[7] Rose MA, Kam PC. Gabapentin: pharmacology and its use in pain management. Anaesthesia 280 
2002;57:451-62. 281 
[8] Ajori L, Nazari L, Mazloomfard MM, Amiri Z. Effects of gabapentin on postoperative pain, 282 
nausea and vomiting after abdominal hysterectomy: a double blind randomized clinical trial. Arch 283 
Gynecol Obstet 2012;285:677-82. 284 
[9] Turan A, Karamanlioğlu B, Memiş D, Usar P, Pamukçu Z, Türe M. The analgesic effects of 285 
gabapentin after total abdominal hysterectomy. Anesth Analg 2004;98:1370-3. 286 
14 
[10] Dierking G, Duedahl TH, Rasmussen ML, Fomsgaard JS, Møiniche S, Rømsing J, et al. Effects 287 
of gabapentin on postoperative morphine consumption and pain after abdominal hysterectomy: a 288 
randomized, double-blind trial. Acta Anaesthesiol Scand 2004;48:322-7. 289 
[11] Sen H, Sizlan A, Yanarates O, Emirkadi H, Ozkan S, Dagli G, et al. A comparison of gabapentin 290 
and ketamine in acute and chronic pain after hysterectomy. Anesth Analg 2009;109:1645-50. 291 
[12] Karbic VO, Škoda M, Antončić D, Krištofić I, Komar D, Trobonjača Z. Gabapentin-induced 292 
changes of plasma cortisol level and immune status in hysterectomized women. Int 293 
Immunopharmacol 2014;23:530-6. 294 
[13] Alayed N, Alghanaim N, Tan X, Tulandi T. Preemptive use of gabapentin in abdominal 295 
hysterectomy: a systematic review and meta-analysis. Obstet Gynecol 2014;123:1221-9. 296 
[14] Steinberg AC, Schimpf MO, White AB, Mathews C, Ellington DR, Jeppson P, et al. Preemptive 297 
analgesia for postoperative hysterectomy pain control: systematic review and clinical practice 298 
guidelines. Am J Obstet Gynecol 2017;217:303-313. 299 
[15] Moore A, Costello J, Wieczorek P, Shah V, Taddio A, Carvalho JC. Gabapentin improves 300 
postcesarean delivery pain management: a randomized, placebo-controlled trial. Anesth Analg 301 
2011;112:167-73. 302 
[16] Monks DT, Hoppe DW, Downey K, Shah V, Bernstein P, Carvalho JC. A perioperative course of 303 
gabapentin does not produce a clinically meaningful improvement in analgesia after cesarean 304 
delivery: a randomized controlled trial. Anesthesiology 2015;123:320-6. 305 
[17] Short J, Downey K, Bernstein P, Shah V, Carvalho JC. A single preoperative dose of gabapentin 306 
does not improve postcesarean delivery pain management: a randomized, double-blind, placebo-307 
controlled dose-finding trial. Anesth Analg 2012;115:1336-42. 308 
[18] Mkontwana N, Novikova N. Oral analgesia for relieving post-caesarean pain. Cochrane Database 309 
Syst Rev 2015;3:Cd010450. 310 
15 
[19] Valadan M, Banifatemi S, Yousefshahi F. Preoperative gabapentin to prevent postoperative 311 
shoulder pain after laparoscopic ovarian cystectomy: a randomized clinical trial. Anesth Pain 312 
Med 2015;5:e31524. 313 
[20] Felder L, Saccone G, Scuotto S, Monks DT, Carvalho JCA, Zullo F, et al. Perioperative 314 
gabapentin and post cesarean pain control: A systematic review and meta-analysis of randomized 315 
controlled trials. Eur J Obstet Gynecol Reprod Biol 2019;233:98-106. 316 
[21] Farrar JT, Polomano RC, Berlin JA, Strom BL. A comparison of change in the 0-10 numeric 317 
rating scale to a pain relief scale and global medication performance scale in a short-term clinical 318 
trial of breakthrough pain intensity. Anesthesiology 2010;112:1464-72. 319 
[22] Gray BA, Hagey JM, Crabtree D, Wynn C, Weber JM, Pieper CF, et al. Gabapentin for 320 
perioperative pain management for uterine aspiration: A randomized controlled trial. Obstet 321 
Gynecol 2019;134:611-9. 322 
[23] Schivone GB, Lerma K, Montgomery C, Wright P, Conti JA, Blumenthal PD, et al. Self-323 
administered lidocaine gel for local anesthesia prior to osmotic dilator placement: a randomized 324 
trial. Contraception 2019;99:148-51. 325 
[24] Creinin MD. Mifepristone vs. osmotic dilator insertion for cervical preparation prior to surgical 326 
abortion at 14-16 weeks: a randomized trial. Contraception 2013;87:507-8. 327 
16 
Figure 1. Flow and follow-up completion of subjects receiving gabapentin or placebo with 
cervical dilator placement before dilation and evacuation procedure 
 
 
NRS = Numeric rating scale   
 
 
121 Women Randomized 
2 Discontinued 
− 1 allergic 
reaction after 
dilator 
placement 
− 1 randomized 
to incorrect 
parity group 
61 Gabapentin 60 Placebo 
60 Gabapentin 58 Placebo 
1 Discontinued 
− No NRS pain 
results 
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Figure 2. Gabapentin-related side effects of dizziness and tiredness in subjects receiving gabapentin 
or placebo with osmotic dilator placement before dilation and evacuation procedure (N=118) 
 
Figure 2A. Dizziness after osmotic dilator placement 
 
 
Figure 2B. Tiredness after osmotic dilator placement 
 
 
Measured using an 11-point numeric rating scale (scale 0-10).  
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Table 1. Baseline characteristics of subjects randomized to receive gabapentin or placebo 
with cervical dilator placement before dilation and evacuation procedure  
 
Characteristic Gabapentin 
n=60 
Placebo 
n=58 
 
P value 
Age (years) 25.4±5.6 27.2±6.1 0.09 
Gestational age 
 15w0d – 19w6d 
 20w0d – 23w5d 
 
41 (68%) 
19 (32%) 
 
33 (57%) 
25 (43%) 
0.25 
Reason for abortion 
 Unwanted pregnancy 
 Fetal anomalies 
 
53 (88%) 
7 (12%) 
 
51 (88%) 
7 (12%) 
0.20 
Race 
 White 
 Black 
 Asian  
 Mixed 
 Other 
 Declined 
 
23 (38%) 
11 (18%) 
7 (12%) 
14 (23%) 
4 (7%) 
1 (2) 
 
34 (59%) 
11 (19%) 
3 (5%) 
5 (9%) 
2 (3%) 
3 (5%) 
0.09 
Ethnicity 
 Hispanic 
 Non-Hispanic 
 Declined 
 
43 (72%) 
17 (28%) 
0 
 
42 (72%) 
14 (24%) 
2 (3%) 
0.32 
Education 
 Has not completed high school 
 High school or equivalent 
 Some college 
 College or higher 
 Declined 
 
6 (10%) 
30 (50%) 
16 (27%) 
8 (13%) 
0 
 
4 (7%) 
15 (26%) 
32 (55%) 
6 (10%) 
1 (2%) 
0.017 
Gravidity 
 1 
 2 
 3 
 4 
 5 
 6 
 7 or more 
 
14 (23%) 
15 (25%) 
11 (18%) 
5 (8%) 
4 (7%) 
4 (7%) 
7 (12%) 
 
10 (17%) 
13 (22%) 
13 (22%) 
7 (12%) 
3 (5%) 
7 (12%) 
5 (9%) 
0.86 
Prior vaginal delivery 
 0 
 1 
 2 
 3 or more 
 
30 (50%) 
16 (27%) 
8 (13%) 
6 (10%) 
 
29 (50%) 
13 (22%) 
9 (16%) 
7 (12%) 
0.93 
Prior Cesarean delivery 
 0 
 1 
 
45 (75%) 
9 (15%) 
 
44 (76%) 
9 (16%) 
0.97 
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 2 or more 6 (10%) 5 (9%) 
Prior miscarriage 12 (20%) 11 (19%) 1.0 
Prior abortion 22 (37%) 27 (47%) 0.35 
History of anxiety 6 (10%) 9 (16%) 0.42 
History of depression 3 (5%) 5 (9%) 0.49 
History of chronic pain 0 2 (3%) 0.24 
History of drug use 
 None 
 Marijuana 
 Methamphetamine 
 Multiple drugs 
 
46 (77%) 
7 (12%) 
4 (7%) 
3 (5%) 
 
42 (72%) 
11 (19%) 
3 (5%) 
2 (3%) 
0.71 
 
Data presented as mean ± standard deviation or n (%). 
w=weeks; d=days
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Table 2. Median change in NRS pain score from baseline among women with osmotic dilators in place prior to dilation and evacuation procedure 
 
 Time after dilator 
placement 
Gabapentin 
n=60 
Placebo 
n=59 
p-value* 
  n Median NRS pain 
score change 
n Median NRS pain 
score change 
 
Total population 
(N=118) 
5 minutes 60 1 (-6, 10) 58 2 (-5, 8) 0.42 
2 hours 54 3.5 (-8, 9) 54 4 (-2, 10) 0.57 
4 hours 56 3 (-8, 9) 50 3.5 (-3, 10) 0.39 
8 hours 58 2 (-3, 8) 52 2.5 (-5, 10) 0.52 
18-24 hours 60 0.5 (-8, 7) 58 1 (-2, 9) 0.23 
Vaginally nulliparous 
(n=59) 
5 minutes 30 0 (-6, 8) 29 2 (-2, 7) 0.09 
2 hours 27 4 (-8, 9) 27 5 (0, 9) 0.26 
4 hours 28 3 (-8, 9) 26 5 (-1, 8) 0.35 
8 hours 29 2 (-3, 8) 28 4 (-2, 7) 0.10 
18-24 hours 30 0.5 (-8, 6) 29 1 (-2, 9) 0.12 
Vaginally parous 
(n=59) 
5 minutes 30 2 (-5, 10) 29 2 (-5, 8) 0.54 
2 hours 27 3 (-1, 9) 27 2 (-2, 10) 0.81 
4 hours 28 3 (-3, 7) 24 2.5 (-3, 10) 0.93 
8 hours 29 2 (-2, 7) 24 1.5 (-5, 10) 0.37 
18-24 hours 30 0.5 (-3, 7) 29 1 (0, 8) 0.95 
 
Data presented as median (range) 
NRS = Numeric rating scale (overall range 0-10) 
*Mann Whitney U test  
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Table 3. Maximum NRS pain score with osmotic dilators and use of acetaminophen with codeine and/or ibuprofen 
Categorization of 
NRS pain score 
Number of women 
reporting NRS and 
analgesic data 
n=118 
Used 
acetaminophen 
with codeine* 
n=75 (64%) p value† 
Used 
Ibuprofen only 
n=23 (20%) p value‡ 
Used no 
analgesics 
n=20 (17%) p value§ 
        
Severe (7-10) 46 (40%) 37 (49%) <0.01 5 (22%) 0.94 4 (20%) 0.02 
Moderate (4-6) 34 (29%) 23 (31%) 6 (26%) 5 (25%) 
Mild (1-3) 33 (28%) 15 (20%) 10 (43%) 8 (40%) 
None (0) 5 (4%) 0 2 (9%) 3 (15%) 
 
Data presented as n (%) 
NRS = Numeric rating scale (overall range 0-10) 
*Includes women who used both acetaminophen with codeine and ibuprofen 
† Chi-square test; p-value is compared to no use of acetaminophen with codeine 
‡ Chi-square test; p-value is compared to use of no pain medication 
§ Chi-square test; p-value is compared to use of any pain medication  
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Table 4. Population median NRS pain scores and proportion with severe pain stratified by vaginal parity among women receiving placebo with 
osmotic dilator placement before dilation and evacuation procedure 
 
Time after dilator 
placement 
Vaginally Nulliparous 
(n=29) 
 
Vaginally Parous 
(n=29) 
p-value* 
 Number 
responding 
NRS Median 
(range) 
Severe pain† Number 
responding 
NRS Median 
(range) 
 
Severe pain† 
Baseline 29 0 (0, 6) 0 29 0 (0, 6) 0 0.72 
5 minutes 29 2 (0, 9) 3 (10%) 29 2 (0, 8) 3 (10%) 0.88 
2 hours 27 6 (0, 10) 9 (33%) 27 3 (0, 10) 7 (26%) 0.09 
4 hours 26 5 (0, 8) 7(27%) 24 3.5 (0, 10) 5 (21%) 0.19 
8 hours 28 5 (0, 10) 5 (18%) 24 2 (0, 10) 2 (8%) 0.008 
18-24 hours 29 2 (0, 10) 6 (21%) 29 2 (0, 8) 2 (7%) 0.51 
 
Data presented as median (range) 
NRS = Numeric rating scale (overall range 0-10) 
*Mann Whitney U test comparing medians 
† Severe pain is NRS score of 7-10 
Online Appendix Figure 1. Pre-operative Cervical Preparation: Use of Dilapan and Mifepristone 
 
Gestational Age 
(weeks) 
Treatment Option 
15 Dilapan #2 
16-17+ Dilapan #3 
18-19+ Dilapan #4 
20-20+ Dilapan #5 
21-21+ Dilapan #6 
22-23+ Dilapan #7-8   AND   Mifepristone* 
 
 
 
Gestational Age 
(weeks) 
Provide adjunctive 
mifepristone* if only 
placed: 
Use second set of 
dilators if only 
placed: 
12-13+ -- -- 
14-15+ -- -- 
16-17+ 1 dilator -- 
18-19+ 2 dilators 1 dilator 
20-20+ 3 dilators 2 dilators 
21-21+ 4 dilators 3 dilators 
22-23+ -- 4 dilators 
 
* Mifepristone 200 mg one day before procedure 
Online Appendix Figure 2.  Population median pain scores among subjects receiving gabapentin or placebo 
with osmotic dilator placement before dilation and evacuation procedure 
 
Figure 2A. Vaginally nulliparous women (n=59) 
 
 
 
 
 
Figure 2B. Vaginally parous women (n=59) 
 
 
 
 
 
NRS = Numeric rating scale (overall range 0-10). 
 p=0.80 p=0.14 p=0.31 p=0.41 p=0.14 p=0.12 
range 
Gabapentin 0-8 0-8 0-9 0-8 0-8 0-8 
Placebo 0-6 0-9 0-10 0-8 0-10 0-10 
 p=0.50 p=0.49 p=0.98 p=0.72 p=0.31 p=0.74 
range 
Gabapentin 0-6 0-10 0-7 0-7 0-7 0-9 
Placebo 0-6 0-8 0-10 0-10 0-10 0-8 
 
